Axikin Pharmaceuticals Gets $3M

San Diego-based Axikin Pharmaceuticals, a new startup focused on small molecule therapeutics for respiratory and inflammatory disease, announced Thursday that it has raised $3M in a Series A funding. The company, which is a spinout of Actimis, said the funding was led by Sanderling Ventures, and also included Mitsui & Co. Venture Partners. Axikin's compounds are targeted at treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. Kevin B. Bacon is founder, President, and Chief Scineitif Officer at the firm; he was the original founder of Actimis. Sanderling's Peter C.M. McWilliams is acting CEO. More information »